Abstract:Asprosin is a newly discovered adipokines. Its main function is to induce hepatic glucose synthesis, promote islet β-cell inflammation, dysfunction, apoptosis,inhibit insulin secretion, and raise blood sugar. In recent years, there is increasing evidence that Asprosin is closely related to the pathophysiological processes of obesity, type 2diabetes, polycystic ovary syndrome, and other metabolic diseases. This article reviews the new role of asporsin in metabolic diseases from the overview of Asprosin, its clinical observations of its changes in the above diseases and the possible mechanisms involved.